Is NCT06307665 recruiting in Phoenix, AZ?

Yes, NCT06307665 is currently recruiting participants at its Phoenix, AZ location. This asthma clinical trial is actively enrolling qualified participants.

How do I join the asthma clinical trial in Phoenix?

To join this clinical trial in Phoenix, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Phoenix clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Asthma Clinical Trial in Phoenix, AZ

About This Asthma Study in Phoenix

The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Confirmed clinical diagnosis of asthma at least 12 months.

Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month

Low-to-high-dose Inhaled corticosteroid(s) (ICS)

Low-to-high-dose ICS or ICS/long-acting β2-agonist (LABA) with or without one additional maintenance therapy from the following: leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline

Receiving inhaled short-acting β2-agonist (SABA) as needed.

A documented history of at least one severe asthma exacerbation within 12 months.

Use of Sponsor-provided albuterol sulfate inhalation aerosol medication.

Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited.

Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator.

Participants must adhere to protocol specific contraception methods.

Negative urine pregnancy test for participants of childbearing potential.

Have a BMI \< 40 kg/ m\^2.

Capable of giving assent (signing the assent form) to participate in the study which includes compliance with the requirements and restrictions. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.

Exclusion Criteria

Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).

Experienced \> 3 severe asthma exacerbations within 12 months before screening.

Completed treatment for lower respiratory infection and severe asthma exacerbation with SCS within 4 weeks of screening.

Upper respiratory infection involving antibiotic treatment not resolved.

Current smokers, former smokers with \> 10 pack-years history, or former smokers who stopped smoking \< 6 months (including all forms of tobacco, e-cigarettes \[vaping\], and marijuana).

Other significant lung disease, including regular or occasional use of oxygen.

Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, or gastrointestinal disorders.

Cancer not in complete remission for at least 5 years.

History or hospitalization for psychiatric disorder or attempted suicide within one year.

Significant abuse of alcohol or drugs, in the opinion of the investigator.

Oral corticosteroid(s) (OCS)/SCS use (any dose and any indication) within 4 weeks before Visit 1 or chronic use of OCS/SCS (≥ 3 weeks use in 3 months prior to Visit 1).

Use of any oral SABAs within one month.

Having a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Phoenix?

Yes, this clinical trial (NCT06307665) has an active research site in Phoenix, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Asthma Treatment Options in Phoenix, AZ

If you're searching for asthma treatment options in Phoenix, AZ, this clinical trial (NCT06307665) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Phoenix research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced asthma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all asthma clinical trials near you to find additional studies recruiting in your area.

Asthma Clinical Trial in Phoenix, AZ

Expert Care in Phoenix

IRB Approved

No-Cost Care

Apply for This Phoenix Location

Why Participate?

Simple Process